Primary Indication: Essential Tremor
A Targeted Small Molecule Approach to Essential Tremor
Developing DK-I-56-1, a differentiated GABA-A subtype-selective therapy designed to address the unmet need in essential tremor.
Selective Mechanism: Cerebellar GABA-A subtype targeting
Development Stage: Preclinical
Partnering Strategy: Milestone-driven value creation
Essential Tremor
A common movement disorder characterized by involuntary shaking, most often affecting the hands during action and daily activities.
Action Tremor
Shaking worsens during purposeful movement and daily tasks.
Severe Quality-of-Life Impact
Writing, eating, and fine motor tasks become difficult or impossible.
Chronic, Progressive Burden
Symptoms often worsen over time, limiting independence.
Current Treatment Landscape
Approved therapies exist, but many patients remain inadequately controlled.
First-line treatment relies on beta-blockers and anticonvulsants.
Propranolol & Primidone as Standard of Care
Often limited by incomplete efficacy, side effects, or contraindications.
Market Opportunity
~7M
Patients in the United States
Significant commercial opportunity in essential tremor
Current Treatment Landscape
Propranolol & Primidone
- FDA-approved first-line therapies
- Broad CNS and systemic effects
- Non-selective mechanism of action
- Established but incomplete efficacy in many patients
Efficacy & Tolerability Limits
- Fatigue, sedation, and bradycardia
- Contraindications in asthma and heart disease
- Many patients seek additional or alternative options
A substantial portion of essential tremor patients remain inadequately treated.
Significant unmet need for a selective, better-tolerated alternative.
The Asset
DK-I-56-1
DK-I-56-1
A novel small-molecule therapy designed to selectively modulate a rare GABA-A receptor subtype expressed in cerebellar circuits involved in tremor control.
- Small-molecule neuromodulator
- Targets a rare GABA-A receptor subtype
- Designed for selective cerebellar circuit modulation
Selective Targeting
Designed to act on a rare GABA-A subtype rather than broadly affecting CNS receptors.
Improved Tolerability Potential
Selective modulation may reduce sedation and CNS side effects associated with existing therapies.
Preclinical Evidence
Demonstrated activity in validated preclinical models of tremor.
Development Strategy
A focused path to clinical value creation.
Head-to-Head Preclinical Study
Comparing DK-I-56-1 directly against standard-of-care therapies in validated tremor models.
Demonstrate Differentiation
Generate data supporting selective targeting and improved CNS tolerability.
Partner for Clinical Development
Advance toward licensing or strategic partnership following successful preclinical results.
Milestones and Use of Funds
The next value-creation phase.
600K Raise
Funding a focused preclinical validation program.
Head-to-Head Study
Execute preclinical comparison of DK-I-56-1 vs standard-of-care therapies.
Data Generation
Establish differentiation in efficacy and tolerability.
Business Development
Engage potential pharmaceutical partners.
Value Inflection
Position the program for licensing or strategic partnership.
A clear partnering milestone.
Generating the data needed to support strategic collaboration.
Traction & Credibility
Early validation from industry and research partners.
Pharma Collaboration
Prior development partnership with a major pharmaceutical company.
CRO Continuity
The same CRO team that advanced the previous program remains engaged.
Partner Interest
Early conversations with potential pharmaceutical partners.
Positioned for strategic partnership.
Focused execution with experienced collaborators.
Leadership Team
Experienced scientists advancing targeted neurological therapeutics.
Michael Hendrickson
18 years in neuroscience & drug development; former Director of Preclinical Development and VP of Operations.
Joseph Beck, PhD
Neuroscientist and serial entrepreneur with three successful startups.
Barry Steiglitz, PhD
18 years pre-clinical research, including serving as principal investigator.
Alex Kasper
20 years of CFO experience, including 14 years in small pharmaceutical companies.
Proven track record in neuroscience ventures.
The team previously partnered a small-molecule asset to MapLight Therapeutics, contributing to $600M in fundraising and a $300M IPO.
Ready to explore the opportunity?
NeuroSolis is advancing a differentiated preclinical therapy for essential tremor, targeting cerebellar circuits through selective GABA-A modulation.
For investor inquiries, partnering discussions, or access to additional diligence materials, contact the NeuroSolis team below.
- Investor Inquiries
- Partnering Discussions
- Request Data Room Access